HRT Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

HRT Financial’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,300	Closed	-$8.12M	–	2970
2023 Q2	$8.12M	Buy	11,300 +6,800	+151%	+$5.24M	0.08%	183
2023 Q1	$3.7M	Buy	+4,500	New	+$3.39M	0.05%	342
2022 Q3	–	Sell	-700	Closed	-$413K	–	3377
2022 Q2	$413K	Buy	+700	New	+$455K	﹤0.01%	1808
2021 Q4	–	Sell	-2,600	Closed	-$1.57M	–	3923
2021 Q3	$1.57M	Buy	+2,600	New	+$1.61M	0.01%	889
2021 Q2	–	Sell	-6,900	Closed	-$3.26M	–	3415
2021 Q1	$3.26M	Buy	+6,900	New	+$3.36M	0.03%	391
2020 Q4	–	Sell	-3,400	Closed	-$1.9M	–	2349
2020 Q3	$1.9M	Buy	+3,400	New	+$2.06M	0.06%	262
2018 Q4	–	Sell	-2,500	Closed	-$1.01M	–	728
2018 Q3	$1.01M	Buy	+2,500	New	+$951K	0.16%	101

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

HRT Financial's REGN Position: Q2 2026 in Review

HRT Financial opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 36,092 shares worth $22.5M. The stake represents 0.04% of the portfolio and ranks #428 among its holdings. This is a return to the name: HRT Financial previously reported a position in REGN as recently as Q3 2025.

HRT Financial first reported a position in REGN in Q3 2015 and has held it in 18 quarters since. The position peaked at $55.6M in Q3 2025. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

HRT Financial held 36,092 shares of Regeneron Pharmaceuticals worth $22.5M as of Q2 2026.
Regeneron Pharmaceuticals was a new HRT Financial position in Q2 2026.
Regeneron Pharmaceuticals made up 0.04% of HRT Financial's portfolio in Q2 2026, its #428 holding.
HRT Financial first reported a position in Regeneron Pharmaceuticals in Q3 2015 and has held it in 18 quarters since.
HRT Financial's Regeneron Pharmaceuticals position peaked at $55.6M in Q3 2025.
1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.